Accéder au contenu
Merck

MABN11

Anti-Beta (β)-Amyloid antibody

mouse monoclonal, G2-10

Synonyme(s) :

Alzheimer disease, Alzheimer disease amyloid protein, Cerebral vascular amyloid peptide, Protease nexin-II, amyloid beta (A4) precursor protein, amyloid beta A4 protein, amyloid beta precursor protein, beta-amyloid peptide, human mRNA for amyloid A4 prec

Se connecter pour consulter les tarifs organisationnels et contractuels.

Sélectionner une taille de conditionnement

Changer de vue

A propos de cet article

UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41
Clone:
G2-10, monoclonal
Species reactivity:
human, mouse
Application:
ELISA, IHC, WB
Citations:
5
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aider


Nom du produit

Anti-Amyloid β40 Antibody, clone G2-10, clone G2-10, from mouse

biological source

mouse

Quality Level

antibody form

purified antibody

antibody product type

primary antibodies

clone

G2-10, monoclonal

species reactivity

human, mouse

technique(s)

ELISA: suitable, immunohistochemistry: suitable, western blot: suitable

isotype

IgG2bκ

NCBI accession no.

UniProt accession no.

shipped in

wet ice

target post-translational modification

unmodified

Gene Information

human ... APP(351)

General description

The cerebral and vascular plaques associated with Alzheimer′s disease (AD) are mainly composed of amyloid beta peptides (Aβ). Aβ is derived from cleavage of the amyloid precursor protein (APP) and varies in length from 39 to 43 amino acids. Aβ [1-40], Aβ [1-42], and Aβ [1-43] peptides result from cleavage of APP after residues 40, 42, and 43, respectively. The cleavage takes place by gamma-secretase during the last APP processing step. Aβ [1-40], [1-42] and [1-43] peptides are major constituents of the plaques and tangles that occur in AD. Aβ antibodies and peptides have been developed as tools for elucidating the biology of AD.
~ 4 kDa

Immunogen

Epitope: C-terminus
Linear peptide of human Amyloid β40 at the C terminus.

Application

Detect Amyloid β40 using this Anti-Amyloid β40 Antibody, clone G2-10 validated for use in WB, IH, ELISA.
Immunohistochemistry Analysis: 1:300 dilution from a previous lot detected Amyloid β40 in Alzheimer’s diseased hippocampus tissue.
Research Category
Neuroscience
Research Sub Category
Neurodegenerative Diseases

Biochem/physiol Actions

This antibody recognizes Amyloid β40 at the C-terminus.

Physical form

Format: Purified
Protein G Purified
Purified mouse monoclonal IgG2bκ in buffer containing 0.1 M Tris-Glycine (pH 7.4, 150 mM NaCl) with 0.05% sodium azide and 1% BSA.

Preparation Note

Stable for 1 year at 2-8°C from date of receipt.

Analysis Note

Control
APP transgenic CRND8 mouse brain lysate
Evaluated by Western Blot in APP transgenic CRND8 mouse brain lysate.

Western Blot Analysis: 1 µg/ml of this antibody detected Amyloid β40 on 10 µg of APP transgenic CRND8 mouse brain lysate.

Other Notes

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.


Still not finding the right product?

Explore all of our products under

ou

Essayez notre Outil de sélection de produits pour affiner vos choix.


Classe de stockage

12 - Non Combustible Liquids

wgk

WGK 1

flash_point_f

Not applicable

flash_point_c

Not applicable



Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents


Contenu apparenté

Alzheimer’s Disease: Amyloid Cascade and Beyond Product Focus


Ditte Z Christensen et al.
Frontiers in aging neuroscience, 6, 139-139 (2014-07-16)
Abnormalities and impairments in axonal transport are suggested to strongly contribute to the pathological alterations underlying AD. The exact mechanisms leading to axonopathy are currently unclear, but it was recently suggested that APP expression itself triggers axonal degeneration. We used
Jin Cui et al.
Cell discovery, 1, 15021-15021 (2015-01-01)
Despite decades of intense global effort, no disease-modifying drugs for Alzheimer's disease have emerged. Molecules targeting catalytic activities of γ-secretase or β-site APP-cleaving enzyme 1 (BACE1) have been beset by undesired side effects. We hypothesized that blocking the interaction between
Vanessa Kurth et al.
The Journal of biological chemistry, 299(8), 104997-104997 (2023-07-03)
Presenilin-1 (PSEN1) is the catalytic subunit of the intramembrane protease γ-secretase and undergoes endoproteolysis during its maturation. Heterozygous mutations in the PSEN1 gene cause early-onset familial Alzheimer's disease (eFAD) and increase the proportion of longer aggregation-prone amyloid-β peptides (Aβ42 and/or



Numéro d'article de commerce international

RéférenceGTIN
MABN1104053252723117